23 October 2024
23 October 2024
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
A year after the first samRNA vaccine approval, experts say similar vaccines in development are likely to face scientific and regulatory hurdles.
Approval has been granted for SELARSDI 130mg/26mL solution in a single-dose vial for intravenous infusion.
This NMA bridges the gap between trials for both therapies and compare them to one another based on existing data.
The approval is based on the Phase III INDIGO clinical trial results.
Editas is partnering its CRISPR platform with Genevant鈥檚 LNP technology to develop novel gene editing medicines in a deal worth $283m.
The International Osteoporosis Foundation highlights the importance of collaborative efforts in treating osteoporosis, ensuring appropriate care globally.
Eli Lilly sued three online vendors and medical spas earlier this week over improper copying of tirzepatide.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
